S&P 500   3,004.52 (+0.28%)
DOW   26,833.95 (+0.17%)
QQQ   192.22 (+0.19%)
AAPL   243.18 (+1.34%)
FB   186.19 (+2.11%)
MSFT   137.24 (+0.64%)
GOOGL   1,257.63 (+1.32%)
AMZN   1,762.17 (-0.20%)
CGC   21.75 (+2.84%)
NVDA   195.09 (-0.27%)
MU   44.66 (+0.00%)
BABA   169.92 (+0.02%)
TSLA   254.68 (-0.35%)
AMD   31.36 (-0.48%)
T   37.74 (-1.13%)
NFLX   271.27 (+1.72%)
BAC   31.42 (+0.71%)
GILD   66.58 (+1.09%)
DIS   131.13 (-0.96%)
S&P 500   3,004.52 (+0.28%)
DOW   26,833.95 (+0.17%)
QQQ   192.22 (+0.19%)
AAPL   243.18 (+1.34%)
FB   186.19 (+2.11%)
MSFT   137.24 (+0.64%)
GOOGL   1,257.63 (+1.32%)
AMZN   1,762.17 (-0.20%)
CGC   21.75 (+2.84%)
NVDA   195.09 (-0.27%)
MU   44.66 (+0.00%)
BABA   169.92 (+0.02%)
TSLA   254.68 (-0.35%)
AMD   31.36 (-0.48%)
T   37.74 (-1.13%)
NFLX   271.27 (+1.72%)
BAC   31.42 (+0.71%)
GILD   66.58 (+1.09%)
DIS   131.13 (-0.96%)
Log in

Check Cap Stock Price, News & Analysis (NASDAQ:CHEK)

$1.70
0.00 (0.00 %)
(As of 10/23/2019 04:00 PM ET)
Today's Range
$1.63
Now: $1.70
$1.72
50-Day Range
$1.72
MA: $1.92
$2.11
52-Week Range
$1.55
Now: $1.70
$4.20
Volume44,508 shs
Average VolumeN/A
Market Capitalization$2.72 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based system that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and colorectal cancers in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a biocompatible unit worn on the patient's back for capsule control, tracking, and data recording; and C-Scan View, a personal computer-based software package, which is designed to retrieve and process clinical data from the C-Scan Track, and to reconstruct and produce 3D visualization of the colon's inner surface. Read More…

Industry, Sector and Symbol

Industry X-ray apparatus & tubes
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CHEK
CUSIPN/A
Phone972-4830-3401

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$8.12 per share

Profitability

Net Income$-10,590,000.00

Miscellaneous

Employees56
Market Cap$2.72 million
Next Earnings Date11/4/2019 (Estimated)
OptionableNot Optionable

Receive CHEK News and Ratings via Email

Sign-up to receive the latest news and ratings for CHEK and its competitors with MarketBeat's FREE daily newsletter.


Check Cap (NASDAQ:CHEK) Frequently Asked Questions

What is Check Cap's stock symbol?

Check Cap trades on the NASDAQ under the ticker symbol "CHEK."

When did Check Cap's stock split? How did Check Cap's stock split work?

Shares of Check Cap reverse split on Wednesday, April 4th 2018. The 1-12 reverse split was announced on Wednesday, April 4th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 3rd 2018. An investor that had 100 shares of Check Cap stock prior to the reverse split would have 8 shares after the split.

How were Check Cap's earnings last quarter?

Check Cap Ltd (NASDAQ:CHEK) released its quarterly earnings data on Wednesday, August, 7th. The medical research company reported ($0.41) earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.05. View Check Cap's Earnings History.

When is Check Cap's next earnings date?

Check Cap is scheduled to release their next quarterly earnings announcement on Monday, November 4th 2019. View Earnings Estimates for Check Cap.

What price target have analysts set for CHEK?

2 equities research analysts have issued 1-year target prices for Check Cap's shares. Their forecasts range from $6.00 to $15.00. On average, they anticipate Check Cap's stock price to reach $10.50 in the next twelve months. This suggests a possible upside of 517.6% from the stock's current price. View Analyst Price Targets for Check Cap.

What is the consensus analysts' recommendation for Check Cap?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Check Cap in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Check Cap.

What are Wall Street analysts saying about Check Cap stock?

Here are some recent quotes from research analysts about Check Cap stock:
  • 1. HC Wainwright analysts commented, "We have assessed Y-mAbs using a discounted cash flow (DCF)-based methodology, which yields a total enterprise value of $1.45B. We utilize a 90% probability of approval for naxitamab in r/r neuroblastoma and for omburtamab in CNS mets from neuroblastoma. We utilize a 60% probability of approval for omburtamab in DIPG. Our discount rate is 10% and effective tax rate is 27.5%. We derive a market value of the firm of roughly $1.45B, which translates into a price per share of $40 assuming 37.8M shares outstanding as of end-1Q20." (7/10/2019)
  • 2. According to Zacks Investment Research, "Check Cap Ltd. is a medical diagnostics company. The company is engaged in the development of an ingestible imaging capsule for the screening of colorectal cancer. Check Cap Ltd. is based in Mount Carmel, Israel. " (5/17/2019)

Has Check Cap been receiving favorable news coverage?

News stories about CHEK stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Check Cap earned a news impact score of 2.0 on InfoTrie's scale. They also gave media headlines about the medical research company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the near term. View News Stories for Check Cap.

Who are some of Check Cap's key competitors?

What other stocks do shareholders of Check Cap own?

Who are Check Cap's key executives?

Check Cap's management team includes the folowing people:
  • Mr. Alex Ovadia, CEO & Director (Age 57)
  • Dr. Yoav Kimchy, Founder & Chief Technology Officer (Age 58)
  • Ms. Mira Rosenzweig, Chief Financial Officer (Age 47)
  • Mr. Lior Torem, Chief Financial Officer (Age 49)
  • Boaz Shpigelman, VP of R&D (Age 47)

When did Check Cap IPO?

(CHEK) raised $13 million in an IPO on Thursday, February 19th 2015. The company issued 1,200,000 shares at $10.00-$12.00 per share. Chardan Capital Markets and Maxim Group served as the underwriters for the IPO and Feltl and Company was co-manager.

How do I buy shares of Check Cap?

Shares of CHEK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Check Cap's stock price today?

One share of CHEK stock can currently be purchased for approximately $1.70.

How big of a company is Check Cap?

Check Cap has a market capitalization of $2.72 million. The medical research company earns $-10,590,000.00 in net income (profit) each year or ($2.61) on an earnings per share basis. Check Cap employs 56 workers across the globe.View Additional Information About Check Cap.

What is Check Cap's official website?

The official website for Check Cap is http://www.check-cap.com/.

How can I contact Check Cap?

Check Cap's mailing address is 29 ABBA HUSHI AVE. P.O.BOX 1271, ISFIYA L3, 3009000. The medical research company can be reached via phone at 972-4830-3401.


MarketBeat Community Rating for Check Cap (NASDAQ CHEK)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  306 (Vote Outperform)
Underperform Votes:  225 (Vote Underperform)
Total Votes:  531
MarketBeat's community ratings are surveys of what our community members think about Check Cap and other stocks. Vote "Outperform" if you believe CHEK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CHEK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel